CSL Says 1st Half Profit Rises, Boosts Dividend
By Mike Cherney
SYDNEY--Australia-based pharmaceuticals company CSL said half-year statutory net profit rose by 17%, reflecting a strong performance in its main blood-plasma business.
CSL said its statutory net profit in the six months through December was US$1.90 billion. That compares to market expectations of US$1.84 billion, as assessed by FactSet. Total statutory revenue rose 12% to US$8.05 billion, compared to market expectations of US$7.94 billion, according to FactSet.
The company declared an interim dividend of US$1.19 per share, compared to US$1.07 in the prior year.
When foreign-exchange movements were stripped out, CSL said its net profit rose by 20% to US$1.94 billion. Underlying profit rose by 13% to US$2.06 billion at constant exchange rates, while annual revenue rose by 11% to US$7.95 billion, CSL said.
Write to Mike Cherney at mike.cherney@wsj.com
(END) Dow Jones Newswires
February 12, 2024 17:00 ET (22:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks